F-1: Empro Group Inc. Files for IPO to Boost Beauty and Healthcare Product Expansion

Empro Group Inc., a Malaysian company specializing in beauty and healthcare products, has filed for an initial public offering (IPO) to fund its expansion plans in ASEAN and European markets.

Summary

• Empro Group Inc., a Cayman Islands exempted company, has filed a Form F-1 registration statement for an IPO.
• The company, through its Malaysian subsidiary EMP Solution, distributes and markets healthcare and beauty products, including its signature triangular eyebrow pencils and medical face masks.
• The IPO aims to raise capital for working capital, market penetration, operating expenses, and transaction expenses.
• For the fiscal year ended December 31, 2023, Empro Group reported total revenue of $3.70 million and a net loss of $0.32 million, a decrease compared to the $10.82 million revenue and $1.17 million net profit in 2022.
• The company intends to list its Ordinary Shares on the Nasdaq Capital Market under the symbol EMPG.
• Prof. Dr. Yeoh Chee Wei, the founder, is expected to beneficially own approximately []% of the outstanding Ordinary Shares after the offering, making Empro Group a controlled company under Nasdaq rules.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the company's history, strengths, and future plans, it also acknowledges a significant decrease in revenue and a net loss in the most recent fiscal year. The company's reliance on a single stockholder and its status as a controlled company also present potential risks to investors.

Positives

• The company has a rich brand history spanning nearly two decades.
• The company has a track record of delivering safe, efficacious, and innovative beauty and healthcare products.
• The company has received numerous accolades and awards for its contributions to the beauty and healthcare industry.
• The company's marketing strategy is adaptable and designed to evolve in response to local market dynamics.
• The company anticipates revenue diversification following the introduction of new products in the beauty segment.
• The company has developed strong relationships with partners, regulators, and government agencies.
• The company boasts a robust and experienced management team.

Negatives

• The company experienced a decrease in total revenue and a net loss in the fiscal year ended December 31, 2023.
• The company's revenue is heavily reliant on the healthcare business segment, which experienced a significant decrease in revenue due to reduced COVID-19 cases.
• The company faces intense competition in the healthcare and beauty industries.
• The company relies on a limited number of ODM/OEM and packaging supply partners to produce its products.
• The company is subject to complex and evolving product safety laws, regulations, and standards.

Risks

• The company operates in a dynamic healthcare and beauty industry and has a limited operating history.
• The company's success is dependent on the continued popularity of its healthcare and beauty products and its ability to anticipate and respond to changes in industry trends and consumer preferences.
• The company's new product introductions may not be as successful as anticipated.
• The company may be subject to infringement claims of intellectual property rights or other rights of third parties.
• The company is controlled by a single stockholder, whose interests in the business may be different than yours.
• The company is a controlled company within the meaning of The Nasdaq Capital Market or, Nasdaq, listing rules.

Future Outlook

The company intends to develop its business and strengthen brand loyalty by expanding product offerings, entering new markets, and investing in new technologies.

Management Comments

• Under the leadership of our founder, Prof. Dr. Yeoh Chee Wei, our company has steadily and successfully transcended its humble origins in the beauty industry during an operating history that spans nearly two decades.
• We believe that this multifaceted strategic synergy will remain pivotal in securing sustained success and a prominent industry position as we navigate into the future.

Industry Context

The beauty market is experiencing significant growth globally and in the Asia-Pacific region, while the PPE market is also expanding, presenting diversified revenue streams for Empro.

Comparison to Industry Standards

• The beauty industry is projected to generate retail sales of $460 billion in 2023, with expectations to reach $580 billion by 2027, demonstrating a compound annual growth rate (CAGR) of approximately 6%, according to McKinsey.
• The APAC region, excluding China, is expected to achieve retail sales of $118 billion in 2023, accounting for around 26% of the global market, with a projected CAGR of approximately 7%, reaching $151 billion by 2027.
• Malaysia is forecasted to generate $3.15 billion in revenue in the beauty and personal care market in 2023, with a projected CAGR of 2.59%, reaching a total sector revenue of $3.58 billion by 2028, according to Statista.
• The global PPE market is valued at $80 billion in 2023, with an expected rise to $113 billion in 2029, reflecting a CAGR of 6%, according to Barnes Reports: 2023.
• In the APAC region, PPE holds the largest market share, exceeding 56% in 2023.
• In Malaysia, the PPE market is valued at $481 million in 2023 and is anticipated to grow at a CAGR of 7% from 2023 to 2029, reaching $736 million.

Corporate Governance

Related Party Transactions

• The company has entered into an Exclusive Sole Distribution agreement with Jingga Anggun Sdn Bhd, a company in which the son of the Director of the Company is the sole director.
• The company has entered into an arrangement with Mosfac Sdn Bhd, a company in which the Director of the Company is a 50% shareholder and a director.
• The company has outstanding receivables from Mimo Motor Sdn Bhd, a company in which the Director of the Company is the sole shareholder and a director.
• The company has outstanding receivables from Emptech Upcycle Sdn Bhd, a company in which the Director of the Company is the sole shareholder and a director.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased.
• The company's performance is dependent on the performance of the economy and consumer spending patterns in the countries in which it operates.
• The company's financial performance is subject to political, economic, social, regulatory and other developments in the countries in which it operates.

Next Steps

• The company intends to use the proceeds from this offering for working capital, market penetration and development, operating expenses and transaction expenses.
• The company plans to expand its product offerings with new brands like Premio and Mios, and its SpaceLift skincare product.
• The company intends to expand into new markets within ASEAN and Europe.
• The company has applied to list its Ordinary Shares on the Nasdaq Capital Market under the symbol EMPG.

Key Dates

Keywords

IPO, beauty products, healthcare products, medical face masks, eyebrow pencils, skincare, ASEAN, EMPRO, Nasdaq, EMPG